Tranexamic acid for bleeding in the brain from a stroke
Tests tranexamic acid in adults with bleeding inside the brain from a stroke.
Plain-language title generated from the registry record
Registry title: Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
Key facts
- Where
- Ålesund, Bergen, Bodo, Kristiansand S, Lorenskog, and Oslo, NorwaySee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have had a sudden bleed inside the brain (intracerebral haemorrhage) in the last 4.5 hours and are given tranexamic acid (TXA).
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Spontaneous bleed in the brain, confirmed on a brain scan, within 4.5 hours of onset. If the start time is unknown, within 4.5 hours of when the symptoms were discovered.
- Earlier treatment
- People taking direct oral anticoagulants can join. People taking warfarin or low molecular weight heparin at the time of enrolment cannot join.
Main reasons for not taking part
- Known reason to be treated with TXA, for example traumatic brain injury
- Active seizures, or a current blood clot in a vein or artery
- Known allergy to TXA or normal saline
- Known problem in the brain's structure, such as aneurysm, tumor or arteriovenous malformation
- Very large bleed (more than 60ml), severe coma (Glasgow Coma Scale below 5), or end-of-life care already decided
Read by machine on 9 November 2026.
Where in Norway
- Helse More Og Romsdal HFÅlesund, NorwayTaking people
- Helse Bergen HFBergen, NorwayTaking people
- Nordlandssykehuset HFBodo, NorwayTaking people
- Sorlandet Sykehus HFKristiansand S, NorwayTaking people
- Akershus University HospitalLorenskog, NorwayTaking people
- Oslo University Hospital HFOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- University Of Nottingham
- Trial code
- EU 2022-500587-35-01
- Record updated
- 14 September 2026
- Original description
To assess the clinical effectiveness of TXA after ICH and determine whether TXA should be used in clinical practice. Primary objective: To assess the effect of TXA on early death (≤28days)Read full original descriptionShow less
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
To assess the clinical effectiveness of TXA after ICH and determine whether TXA should be used in clinical practice. Primary objective: To assess the effect of TXA on early death (≤28days)